Fig. 2
From: Precision treatment of Singleton Merten syndrome with ruxolitinib: a case report
Effects of JAK inhibition on skin and interferon signature. A Right elbow before initiation of treatment with ruxolitinib, showing psoriatic lesion with hyperkeratosis and scaling. B Resolution of psoriatic skin lesion after one week of treatment. C Interferon signature before and during treatment with ruxolitinib. An IFN score < 12,49 defines the median of 10 healthy controls plus 2 SDs.The dark blue vertical line marks the start of the treatment with ruxolitinib. The light blue vertical line marks the time when the treatment was increased to the final dosage